Elias Jabbour, MD

Articles

Dr. Jabbour Discusses Recent Advancements in ALL

August 23rd 2018

Elias Jabbour, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses recent advances in the treatment of patients with acute lymphoblastic leukemia.

Dr. Jabbour Discusses Blinatumomab in ALL

August 2nd 2018

Elias Jabbour, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses blinatumomab (Blincyto) in acute lymphoblastic leukemia.

Dr. Jabbour on Emerging Subsets in ALL

October 29th 2016

Elias Jabbour, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses recent treatment advances and emerging subsets in acute lymphoblastic leukemia (ALL).

Dr. Elias Jabbour on Blinatumomab for ALL

May 31st 2016

​Elias Jabbour, MD, associate professor, department of leukemia, division of cancer medicine, the University of Texas MD Anderson Cancer Center, discusses blinatumomab (Blincyto) for acute lymphocytic leukemia (ALL).

Dr. Jabbour on Front-Line Treatments for CML

March 15th 2011

Elias Jabbour, MD, Assistant Professor, Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, discusses front-line treatments for CML, at the 2010 ASCO Annual Meeting.

Dr. Jabbour on Second-Generation TKIs in CML

March 15th 2011

Elias Jabbour, MD, Assistant Professor, Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, on second-generation TKIs for patients with CML, a cancer that starts inside bone marrow.

x